Table 1.
PARAMETER | Mean ± SD or number of patients (%) |
---|---|
Age (years) |
59.0 ± 11.0 |
Gender (male) |
40 (89) |
NYHA class | |
I |
4 (9) |
II |
22 (49) |
III |
15 (33) |
IV |
4 (9) |
Atrial fibrillation |
15 (33) |
Hypercholesterolemia |
20 (46) |
Anemia* |
4 (9) |
Diabetes mellitus or abnormal glucose level |
9 (20) |
LV diastolic dysfunction |
4 (9) |
sPAP >40 mmHg |
4 (9) |
MR degree | |
0 |
7 (15) |
I |
19 (43) |
II |
15 (34) |
III |
4 (9) |
TR degree | |
0 |
23 (51) |
I |
14 (32) |
II |
8 (17) |
PHARMACOLOGICAL TREATMENT | |
Loop diuretics |
41 (91) |
Spironolactone/eplerenone |
39 (87) |
vBeta-blockers |
40 (88) |
ACE inhibitors |
41 (91) |
Sartans (ARBs) |
4 (9) |
Digoxin |
15 (34) |
Acenocoumarol/warfarin |
9 (20) |
Amiodarone |
4 (8) |
Statins |
22 (49) |
Insulin |
2 (4) |
Oral hypoglycemics | 4 (9) |
*Anemia: Hb (g/dL) <13 in men and <12 in women.
ABBREVIATIONS: ACE inhibitors – angiotensin converting enzyme inhibitors; ARB angiotensin receptor blocker; MR mitral regurgitation; NYHA New York heart association; sPAP systolic pulmonary artery pressure; TR tricuspid regurgitation.